US 11,773,390 B2
Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
Bob D. Brown, Littleton, MA (US); and Henryk T. Dudek, Belmont, MA (US)
Assigned to Dicerna Pharmaceuticals, Inc., Lexington, MA (US)
Filed by Dicerna Pharmaceuticals, Inc., Lexington, MA (US)
Filed on Dec. 17, 2020, as Appl. No. 17/125,245.
Application 17/125,245 is a continuation of application No. 16/221,434, filed on Dec. 14, 2018, granted, now 10,954,517.
Application 16/221,434 is a continuation of application No. 15/953,780, filed on Apr. 16, 2018, abandoned.
Application 15/953,780 is a continuation of application No. 15/044,538, filed on Feb. 16, 2016, granted, now 10,036,017, issued on Jul. 31, 2018.
Claims priority of provisional application 62/117,124, filed on Feb. 17, 2015.
Prior Publication US 2021/0139903 A1, May 13, 2021
Int. Cl. C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [C12N 2310/14 (2013.01); C12N 2320/11 (2013.01)] 20 Claims
 
1. A nucleic acid comprising an oligonucleotide strand of up to 80 nucleotides in length, wherein said oligonucleotide strand is complementary to a target C5 mRNA sequence set forth as SEQ ID NO: 1262 along at least 21 consecutive nucleotides of said oligonucleotide strand length to reduce C5 target mRNA expression when said nucleic acid is introduced into a mammalian cell, wherein said dsNA comprises a modified nucleotide.